35 results on '"Papi, Claudio"'
Search Results
2. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology
3. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology
4. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology
5. Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohn’s disease
6. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
7. Management of ulcerative colitis in a real-life setting: An Italian multicenter, prospective, observational AIGO study
8. The use of oral corticosteroids in inflammatory bowel diseases in Italy: An IG-IBD survey
9. Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease
10. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
11. Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD “AGED study”
12. Short term colectomy rate and mortality for severe ulcerative colitis in the last 40 years. Has something changed?
13. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology
14. Intentional treatment with tofacitinib in a patient with severe refractory ulcerative colitis and concomitant Sars-CoV-2 infection
15. Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease
16. Occurrence of inflammatory bowel disease in central Italy: A study based on health information systems
17. Mucosal healing in inflammatory bowel disease: Treatment efficacy and predictive factors
18. Adalimumab in active ulcerative colitis: A “real-life” observational study
19. Platelet count/spleen diameter ratio for non-invasive diagnosis of oesophageal varices: Is it useful in compensated cirrhosis?
20. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease
21. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology
22. No impact of restructuring IBD-related activity during COVID-19 outbreak on patient outcomes. A single Center experience
23. The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When “non-urgent” does not mean “deferrable”
24. Author's Reply: ``Use of biologics for the management of Crohn's disease''
25. Screening for active COVID-19 infection prior to biologic therapy in IBD patients: Let's not increase our uncertainty without reducing our concerns
26. Acute kidney injury: an unexpected Isoniazid-related adverse event in a patient with Crohn's disease receiving prophylactic treatment for latent tuberculosis
27. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
28. Unmet needs of Italian physicians managing patients with inflammatory bowel disease
29. How thiopurines are used for the treatment of inflammatory bowel diseases: An Italian survey
30. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
31. Colonic small cell neuroendocrine carcinoma in a patient with long-standing ulcerative colitis treated with azathioprine
32. Gastrointestinal bleeding and severe anaemia: An uncommon presentation of small bowel carcinoma complicating ileal Crohn's disease
33. Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease
34. Do not disturb the sleeping worm
35. Safety of eradication for Helicobacter pylori: How many patients stop a 7–15 days therapy for side effects? A meta-analysis of randomized trials for dyspepsia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.